Depixus will be presenting at the world’s leading conferences on the advancement of tools and technologies for the advancement of exciting new small molecule therapeutics targeting RNA over the coming months – make sure to tune in to hear about MAGNA™ and how we are addressing some of the key bottlenecks in this new area of drug discovery!
Depixus, will be participating in BSI 2023 from 13 to 17 November, 2023, Marseilles, France.
Dr Adeline Feri (Principal Scientist, Product Development) and Dr Nigel Skinner (Head of Marketing) will be presenting a poster entitled ‘Single molecule real-time analysis of dynamic nucleic acid interactions’.
The Integrative Structural Biology (BSI) congress is jointly organized by the French Association of Crystallography AFC (AFC) and the French Society of Biophysics SFB (SFB). BSI 2023 is the third edition of this congress with the objective of strengthening links between the Structural Biology and Biophysics communities. This event reflects local, regional and national expertise in developmental biology, oncology, chemistry of life, glycobiology, immunology, microbiology, neuroscience, virology, as well as complementary cutting-edge biophysical analytical approaches.
We look forward to meeting you there!
Depixus will be participating in the 6th Annual RNA-Targeted Drug Discovery Summit from 12 to 14 December, 2023, Boston, USA.
As one of the most anticipated events on the RNA calendar, the RNA-Targeted Drug Discovery Summit returns this December. This premier, definitive, and most comprehensive forum for the RNA-targeting small molecule community will address remaining challenges, including but not limited to RNA structure and function relationship, functional validation, and the translational route from discovery to pre-clinical and clinical development.
Dr Pascal Beurdeley, SVP Product Development, will be talking about how Depixus is accelerating the discovery of such novel therapeutics using its powerful new MAGNA™ technology. Don’t miss her presentation, which is entitled ‘Structure-activity relationships: using magnetic force spectroscopy to link in vivo and in vitro data in RNA-targeted small molecule drug discovery.’
We look forward to meeting you there!
Depixus will be participating in the International SLAS Conference, from 3 to 7 February, 2024, Boston Convention & Exhibition Center, USA.
This will be a really exciting event for us for 3 reasons:
SLAS is a global, non-profit professional community made up of scientists from academia, government and industry who are collectively focused on leveraging the power of technology to achieve scientific objectives. A primary part of their mission is to unite great minds in life sciences and technology to transform research.
The International Conference is a very important fixture in this industry and we look forward to meeting you in Boston in Feb 2024!
Depixus will be exhibiting its ground-breaking MAGNA One™ instrument at the Biophysical Society Annual Meeting, from 10 to 14 February, 2024, Pennsylvania Convention Center, Philadelphia, USA.
The theme of this year’s meeting is very appropriate: Biophysics: The Next Generation
As science becomes increasingly interdisciplinary, the Biophysical Society Annual Meeting continues its long-held reputation for bringing together leading scientists from all over the world who work at the interface of the life, physical, and computational sciences. The meeting shares the latest unpublished findings of leading research groups worldwide, as well as highlighting the newest emerging techniques and applications.
We look forward to meeting you at Booth #411 at BPS in Feb 2024!
Depixus will be exhibiting its ground-breaking MAGNA One™ instrument at Booth #301 at the Drug Discovery Chemistry Conference from 1 to 4 April, 2024, San Diego, USA.
Drug Discovery Chemistry highlights advances in current and emerging “hot” targets and technologies, as well as target validation strategies for the discovery and development of novel therapeutic agents ranging from biologics to small molecules.
We look forward to seeing you there!
Depixus will be exhibiting its ground-breaking MAGNA One™ instrument at Booth #515 at the Discovery on Target Conference from 30 September to 3 October, 2024, Boston, USA.
Discovery on Target (DOT) is a dynamic conference for medicinal and biophysical chemists working in pharma, biotech, and academia. Focused on discovery and optimization challenges of small molecule drug candidates, this event provides cutting edge coverage of hot new areas such as small molecules targeting RNA, protein degraders, molecular glues, and artificial intelligence for early drug discovery.
We look forward to seeing you there!
